Imatinib mesylate for the treatment of gastrointestinal stromal tumor

References

• Monges G, Coindre J, Scoazec J et al. Incidence of gastrointestinal stromal tumors (GISTs) in France: results of the PROGIST survey conducted among pathologists. J. Clin. Oncol. (Meeting Abstracts)25(18 Suppl.), 10047 (2007).
   Google Scholar
• Rubio J, Marcos-Gragera R, Ortiz MR et al. Population-based incidence and survival of gastrointestinal stromal tumours (GIST) in Girona, Spain. Eur. J. Cancer43(1), 144–148 (2007).
   PubMed Web of Science ®Google Scholar
• Nilsson B, Bumming P, Meis-Kindblom JM et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer103(4), 821–829 (2005).
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur. J. Cancer41(18), 2868–2872 (2005).
   PubMed Web of Science ®Google Scholar
• Kawanowa K, Sakuma Y, Sakurai S et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum. Pathol.37(12), 1527–1535 (2006).
   PubMed Web of Science ®Google Scholar
• Agaimy A, Wunsch PH, Hofstaedter F et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am. J. Surg. Pathol.31(1), 113–120 (2007).
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann. Surg.231(1), 51–58 (2000).
   PubMed Web of Science ®Google Scholar
• Alvarado-Cabrero I, Vazquez G, Sierra Santiesteban FI, Hernandez-Hernandez DM, Pompa AZ. Clinicopathologic study of 275 cases of gastrointestinal stromal tumors: the experience at 3 large medical centers in Mexico. Ann. Diagn. Pathol.11(1), 39–45 (2007).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am. J. Surg. Pathol.25(9), 1121–1133 (2001).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am. J. Surg. Pathol.29(1), 52–68 (2005).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol.23(2), 70–83 (2006).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Makhlouf H, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am. J. Surg. Pathol.30(4), 477–489 (2006).
   PubMed Web of Science ®Google Scholar
• Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J. Clin. Oncol.22(18), 3813–3825 (2004).
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science279(5350), 577–580 (1998).
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res.61(22), 8118–8121 (2001).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol.21(23), 4342–4349 (2003).
   PubMed Web of Science ®Google Scholar
• Lux ML, Rubin BP, Biase TL et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol.156(3), 791–795 (2000).
   PubMed Web of Science ®Google Scholar
• Lasota J, Wozniak A, Sarlomo-Rikala M et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am. J. Pathol.157(4), 1091–1095 (2000).
   PubMed Web of Science ®Google Scholar
• Rubin BP, Singer S, Tsao C et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res.61(22), 8118–8121 (2001).
   PubMed Web of Science ®Google Scholar
• Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am. J. Pathol.160(5), 1567–1572 (2002).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science299(5607), 708–710 (2003).
   PubMed Web of Science ®Google Scholar
• Corless CL, Schroeder A, Griffith D et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol.23(23), 5357–5364 (2005).
   PubMed Web of Science ®Google Scholar
• Lasota J, Nsonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab. Invest.84(7), 874–883 (2004).
   PubMed Web of Science ®Google Scholar
• Wardelmann E, Hrychyk A, Merkelbach-Bruse S et al. Association of platelet-derived growth factor receptor α mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J. Mol. Diagn.6(3), 197–204 (2004).
   PubMed Web of Science ®Google Scholar
• Agaimy A, Terracciano LM, Dirnhofer S et al. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours. J. Clin. Pathol.62(7), 613–616 (2009).
   PubMed Web of Science ®Google Scholar
• Martinho O, Gouveia A, Viana-Pereira M et al. Low frequency of MAP kinase pathway alterations in KIT and PDGFRA wild-type GISTs. Histopathology55(1), 53–62 (2009).
   PubMedGoogle Scholar
• Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG. NF1-associated gastrointestinal stromal tumors have unique clinical, phenotypic, and genotypic characteristics. Am. J. Surg. Pathol.29(9), 1170–1176 (2005).
   PubMed Web of Science ®Google Scholar
• Pasini B, McWhinney SR, Bei T et al. Clinical and molecular genetics of patients with the Carney–Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur. J. Hum. Genet.16(1), 79–88 (2008).
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res.59(17), 4297–4300 (1999).
   PubMed Web of Science ®Google Scholar
• Singer S, Rubin BP, Lux ML et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J. Clin. Oncol.20(18), 3898–3905 (2002).
   PubMed Web of Science ®Google Scholar
• Blay JY, Bonvalot S, Casali P et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20–21 March 2004, under the auspices of ESMO. Ann. Oncol.16(4), 566–578 (2005).
   PubMed Web of Science ®Google Scholar
• Plaat BE, Hollema H, Molenaar WM et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J. Clin. Oncol.18(18), 3211–3220 (2000).
   PubMed Web of Science ®Google Scholar
• Hsu KH, Yang TM, Shan YS, Lin PW. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor. Am. J. Surg.194(2), 148–152 (2007).
   PubMed Web of Science ®Google Scholar
• Fletcher CD, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol.33(5), 459–465 (2002).
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch. Pathol. Lab. Med.130(10), 1466–1478 (2006).
   PubMed Web of Science ®Google Scholar
• Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw.5(Suppl. 2), S1–S29 (2007).
   PubMedGoogle Scholar
• Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet368(9544), 1329–1338 (2006).
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von MM et al. Long-term results from a randomized Phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol.26(4), 620–625 (2008).
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J. Clin. Oncol.26(4), 626–632 (2008).
   PubMed Web of Science ®Google Scholar
• Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood105(7), 2640–2653 (2005).
   PubMed Web of Science ®Google Scholar
• Dewar AL, Cambareri AC, Zannettino AC et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood105(8), 3127–3132 (2005).
   PubMed Web of Science ®Google Scholar
• Blay JY, El SH, Thiesse P, Garret J, Ray-Coquard I. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann. Oncol.19(4), 821–822 (2008).
   PubMed Web of Science ®Google Scholar
• West RB, Rubin BP, Miller MA et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. Proc. Natl Acad. Sci. USA103(3), 690–695 (2006).
   PubMed Web of Science ®Google Scholar
• Gardner ER, Burger H, van Schaik RH et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin. Pharmacol. Ther.80(2), 192–201 (2006).
   PubMed Web of Science ®Google Scholar
• Champagne MA, Capdeville R, Krailo M et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children’s Oncology Group Phase 1 study. Blood104(9), 2655–2660 (2004).
   PubMed Web of Science ®Google Scholar
• Peng B, Hayes M, Resta D et al. Pharmacokinetics and pharmacodynamics of imatinib in a Phase I trial with chronic myeloid leukemia patients. J. Clin. Oncol.22(5), 935–942 (2004).
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99–08. Clin. Cancer Res.12(16), 4899–4907 (2006).
   PubMed Web of Science ®Google Scholar
• Dutreix C, Peng B, Mehring G et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother. Pharmacol.54(4), 290–294 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Meinhardt P, Bond E et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br. J. Cancer89(10), 1855–1859 (2003).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med.344(14), 1052–1056 (2001).
   PubMed Web of Science ®Google Scholar
• van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet358(9291), 1421–1423 (2001).
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Egorin MJ, Takimoto CH et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J. Clin. Oncol.26(4), 563–569 (2008).
   PubMed Web of Science ®Google Scholar
• Gibbons J, Egorin MJ, Ramanathan RK et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J. Clin. Oncol.26(4), 570–576 (2008).
   PubMed Web of Science ®Google Scholar
• Judson IR. Imatinib for patients with liver or kidney dysfunction: no need to modify the dose. J. Clin. Oncol.26(4), 521–522 (2008).
   PubMed Web of Science ®Google Scholar
• Demetri GD, von MM, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med.347(7), 472–480 (2002).
   PubMed Web of Science ®Google Scholar
• Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs10(4), 239–253 (1992).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Verweij J, Van OA, Blay JY et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II study. Eur. J. Cancer39(14), 2006–2011 (2003).
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst.92(3), 205–216 (2000).
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet364(9440), 1127–1134 (2004).
   PubMed Web of Science ®Google Scholar
• Rankin C, Von Mehren M, Blanke C et al. Dose effect of imatinib (IM) in patients (pts) with metastatic GIST - Phase III Sarcoma Group Study S0033. J. Clin. Oncol. (Meeting Abstracts)22(14 Suppl.), 9005 (2004).
   Google Scholar
• Van Glabbeke MM, Owzar K, Rankin C, Simes J, Crowley J, GIST Meta-analysis Group. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients (pts). J. Clin. Oncol. (Meeting Abstracts)25(18 Suppl.), 10004 (2007).
   Web of Science ®Google Scholar
• Zalcberg JR, Verweij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur. J. Cancer41(12), 1751–1757 (2005).
   PubMed Web of Science ®Google Scholar
• Blay JY, Le CA, Ray-Coquard I et al. Prospective multicentric randomized Phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J. Clin. Oncol.25(9), 1107–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Ray-Coquard I, Bui B et al. Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: a prospective randomized Phase III trial of the French Sarcoma Group. J. Clin. Oncol. (Meeting Abstracts)25(18 Suppl.), 10005 (2007).
   Web of Science ®Google Scholar
• Debiec-Rychter M, Sciot R, Le CA et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J Cancer42(8), 1093–1103 (2006).
   PubMed Web of Science ®Google Scholar
• Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumours: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol.20(Suppl. 4), 64–67 (2009).
   PubMedGoogle Scholar
• Heinrich MC, Maki RG, Corless CL et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J. Clin. Oncol. (Meeting Abstracts)24(18 Suppl.), 9502 (2006).
   Web of Science ®Google Scholar
• Debiec-Rychter M, Cools J, Dumez H et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology128(2), 270–279 (2005).
   PubMed Web of Science ®Google Scholar
• Liegl B, Kepten I, Le C et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J. Pathol.216(1), 64–74 (2008).
   PubMed Web of Science ®Google Scholar
• Loughrey MB, Waring PM, Dobrovic A, Demetri G, Kovalenko S, McArthur G. Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors. Clin. Cancer Res.12(20 Pt 1), 6205–6206 (2006).
   PubMedGoogle Scholar
• Wardelmann E, Merkelbach-Bruse S, Pauls K et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin. Cancer Res.12(6), 1743–1749 (2006).
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J. Clin. Oncol.26(33), 5352–5359 (2008).
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Owzar K, Antonescu CR et al. Efficacy of adjuvant imatinib mesylate following complete resection of localized, primary gastrointestinal stromal tumor (GIST) at high risk of recurrence: the US Intergroup Phase II trial ACOSOG Z9000. Presented at. the 2008 Gastrointestinal Cancer Symposium. Orlando, FL, USA 25–27 January 2008 Orlando FL
   Google Scholar
• Nilsson B, Sjolund K, Kindblom LG et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br. J. Cancer96(11), 1656–1658 (2007).
   PubMed Web of Science ®Google Scholar
• Li J, Gong FJ, Li J, Wu WA, Shen L. Adjuvant therapy with imatinib in gastrointestinal stromal tumor (GIST) patients with intermediate or high risk: analysis from a single-center contrast study. J. Clin. Oncol. (Meeting Abstracts)27(15S), 10556 (2009).
   Google Scholar
• Kang B Sr, Lee J, Ryu M et al. A Phase II study of imatinib mesylate as adjuvant treatment for curatively resected high-risk localized gastrointestinal stromal tumors. J. Clin. Oncol. (Meeting Abstracts)27(15S), e21515 (2009).
   Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet373(9669), 1097–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med.12(8), 908–916 (2006).
   PubMed Web of Science ®Google Scholar
• Trent JC, Patel SS, Zhang J et al. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer116(1), 184–192 (2010).
   PubMed Web of Science ®Google Scholar
• Pilot PR, Sablinska K, Owen S, Hatfield A. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia20(1), 148 (2006).
   PubMed Web of Science ®Google Scholar
• Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia19(9), 1689–1692 (2005).
   PubMed Web of Science ®Google Scholar
• Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). J. Clin. Oncol. (Meeting Abstracts)24(18 Suppl.), 6119 (2006).
   Web of Science ®Google Scholar
• Demetri GD, Benjamin RS, Blanke CD et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST) – update of the NCCN clinical practice guidelines. J. Natl Compr. Canc. Netw.5(Suppl. 2), S1–S29 (2007).
   PubMedGoogle Scholar
• Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J. Clin. Oncol.25(13), 1760–1764 (2007).
   PubMed Web of Science ®Google Scholar
• Le Cesne A, Van GM, Verweij J et al. Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC–ISG–AGITG Phase III trial. J. Clin. Oncol.27(24), 3969–3974 (2009).
   PubMedGoogle Scholar
• Heinrich MC, Owzar K, Corless CL et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J. Clin. Oncol.26(33), 5360–5367 (2008).
   PubMed Web of Science ®Google Scholar
• Demetri GD, Casali PG, Blay JY et al. A Phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin. Cancer Res.15(18), 5910–5916 (2009).
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S et al. Nilotinib demonstrates superior efficacy compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: results from the international randomized Phase III ENESTnd trial. Presented at: 2009 Meeting of the American Society of Hematology. New Orleans, LA, USA 5–8 December 2009.
   Google Scholar
• Schittenhelm MM, Shiraga S, Schroeder A et al. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res.66(1), 473–481 (2006).
   PubMed Web of Science ®Google Scholar
• Dewaele B, Wasag B, Cools J et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin. Cancer Res.14(18), 5749–5758 (2008).
   PubMed Web of Science ®Google Scholar